Literature DB >> 21289244

Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas.

Jessica Costa-Guda1, Ilaria Marinoni, Sara Molatore, Natalia S Pellegata, Andrew Arnold.   

Abstract

CONTEXT: Typical nonfamilial (sporadic) parathyroid adenomas are common endocrine tumors for which no predisposing germline DNA variants and only a few clonally altered genes that drive parathyroid tumorigenesis have been identified. CDKN1B, encoding cyclin-dependent kinase inhibitor p27(kip1), has recently been implicated in a multiple endocrine tumor phenotype in rats and, rarely, in a human familial MEN1 (multiple endocrine neoplasia type 1)-like disorder.
OBJECTIVE: We sought to determine whether mutation of CDKN1B might contribute to the development of common sporadic parathyroid adenomas. PATIENTS AND
DESIGN: We sequenced the CDKN1B gene in 86 parathyroid adenomas from patients with typical, sporadic presentations of primary hyperparathyroidism. Identified alterations were categorized as somatic or germline, and their functional consequences were examined.
RESULTS: CDKN1B sequence abnormalities were identified in four parathyroid adenomas. Acquired biallelic alteration of CDKN1B, resulting from somatic mutation plus loss of heterozygosity, was detected in one tumor. Germline origin was documented in two cases despite nonfamilial presentations. None of the observed alterations were found in 240 CDKN1B alleles from normal individuals, nor among more than 2,000 previously reported alleles. Most identified variants reduced p27(kip1) protein levels or altered in vitro stability.
CONCLUSIONS: In typical, sporadic parathyroid adenomas, CDKN1B mutation can be somatic and clonal, indicative of a directly conferred selective advantage in parathyroid tumorigenesis. Additionally, the identification of germline CDKN1B variants in patients with sporadic presentations provides evidence for CDKN1B as a susceptibility gene in the development of typical parathyroid adenomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289244      PMCID: PMC3070245          DOI: 10.1210/jc.2010-1338

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors.

Authors:  Feng Bai; Xin-Hai Pei; Toru Nishikawa; Matthew D Smith; Yue Xiong
Journal:  Mol Cell Biol       Date:  2006-12-04       Impact factor: 4.272

2.  Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.

Authors:  Natalia S Pellegata; Leticia Quintanilla-Martinez; Heide Siggelkow; Elenore Samson; Karin Bink; Heinz Höfler; Falko Fend; Jochen Graw; Michael J Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-09       Impact factor: 11.205

3.  Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function.

Authors:  Daniel Lindberg; Göran Akerström; Gunnar Westin
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

4.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

5.  Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.

Authors:  K B Lauter; A Arnold
Journal:  Kidney Int       Date:  2008-02-20       Impact factor: 10.612

Review 6.  Common and rare variants in multifactorial susceptibility to common diseases.

Authors:  Walter Bodmer; Carolina Bonilla
Journal:  Nat Genet       Date:  2008-06       Impact factor: 38.330

7.  Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors.

Authors:  S Takeuchi; H P Koeffler; D R Hinton; I Miyoshi; S Melmed; I Shimon
Journal:  J Endocrinol       Date:  1998-05       Impact factor: 4.286

8.  Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia.

Authors:  Marianthi Georgitsi; Anniina Raitila; Auli Karhu; Rob B van der Luijt; Cora M Aalfs; Timo Sane; Outi Vierimaa; Markus J Mäkinen; Karoliina Tuppurainen; Ralph Paschke; Oliver Gimm; Christian A Koch; Sadi Gündogdu; Anneke Lucassen; Marc Tischkowitz; Louise Izatt; Simon Aylwin; Gul Bano; Shirley Hodgson; Ernesto De Menis; Virpi Launonen; Pia Vahteristo; Lauri A Aaltonen
Journal:  J Clin Endocrinol Metab       Date:  2007-05-22       Impact factor: 5.958

9.  Mutational analysis of the cell cycle inhibitor Kip1/p27 in childhood leukemia.

Authors:  E-A Markaki; E Stiakaki; A Zafiropoulos; D A Arvanitis; N Katzilakis; H Dimitriou; D A Spandidos; M Kalmanti
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

10.  Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.

Authors:  N Kawamata; T Seriu; H P Koeffler; C R Bartram
Journal:  Cancer       Date:  1996-02-01       Impact factor: 6.860

View more
  36 in total

Review 1.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

2.  Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins.

Authors:  Jessica Costa-Guda; Yasuo Imanishi; Nallasivam Palanisamy; Norihiko Kawamata; H Phillip Koeffler; R S K Chaganti; Andrew Arnold
Journal:  Endocrine       Date:  2013-02-24       Impact factor: 3.633

3.  EZH2 copy number and mutational analyses in sporadic parathyroid adenomas.

Authors:  Robert Romano; Chen-Pang Soong; Madison Rose; Jessica Costa-Guda; Justin Bellizzi; Andrew Arnold
Journal:  Endocrine       Date:  2016-10-14       Impact factor: 3.633

Review 4.  Multiple endocrine neoplasia syndromes associated with mutation of p27.

Authors:  M Lee; N S Pellegata
Journal:  J Endocrinol Invest       Date:  2013-06-26       Impact factor: 4.256

5.  CDK4/6 Dependence of Cyclin D1-Driven Parathyroid Neoplasia in Transgenic Mice.

Authors:  Jessica Costa-Guda; Kristin Corrado; Justin Bellizzi; Robert Romano; Elizabeth Saria; Kirsten Saucier; Madison Rose; Samip Shah; Cynthia Alander; Sanjay Mallya; Andrew Arnold
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

Review 6.  Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Authors:  Jonathan D Wasserman; Gail E Tomlinson; Harriet Druker; Junne Kamihara; Wendy K Kohlmann; Christian P Kratz; Katherine L Nathanson; Kristian W Pajtler; Andreu Parareda; Surya P Rednam; Lisa J States; Anita Villani; Michael F Walsh; Kristin Zelley; Joshua D Schiffman
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

Review 7.  MEN4 and CDKN1B mutations: the latest of the MEN syndromes.

Authors:  Rami Alrezk; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2017-08-19       Impact factor: 5.678

Review 8.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

9.  Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.

Authors:  Jessica Costa-Guda; Chen-Pang Soong; Vaishali I Parekh; Sunita K Agarwal; Andrew Arnold
Journal:  Horm Cancer       Date:  2013-05-29       Impact factor: 3.869

Review 10.  Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes.

Authors:  M Cristina Pacheco
Journal:  J Pediatr Genet       Date:  2016-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.